Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
Jinghua Wang, Guoping Wu, Brian Manick, et al.
Immunology (2018) Vol. 156, Iss. 1, pp. 74-85
Open Access | Times Cited: 220

Showing 1-25 of 220 citing articles:

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Golnaz Morad, Beth A. Helmink, Padmanee Sharma, et al.
Cell (2021) Vol. 184, Iss. 21, pp. 5309-5337
Open Access | Times Cited: 1070
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin, Linping Xu, Ming Yi, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 960
VISTA is an acidic pH-selective ligand for PSGL-1
Robert J. Johnston, Linhui Julie Su, Jason Pinckney, et al.
Nature (2019) Vol. 574, Iss. 7779, pp. 565-570
Closed Access | Times Cited: 293
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Reem Saleh, Eyad Elkord
Cancer Letters (2020) Vol. 490, pp. 174-185
Open Access | Times Cited: 249
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto, Francheska Caminero, Lindsay Cash, et al.
Translational Oncology (2020) Vol. 13, Iss. 3, pp. 100738-100738
Open Access | Times Cited: 234
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Reem Saleh, Eyad Elkord
Seminars in Cancer Biology (2019) Vol. 65, pp. 13-27
Closed Access | Times Cited: 222
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Duaa O. Khair, Heather J. Bax, Silvia Mele, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 220
Immune checkpoints in the tumor microenvironment
Salman M. Toor, Varun Sasidharan Nair, Julie Decock, et al.
Seminars in Cancer Biology (2019) Vol. 65, pp. 1-12
Closed Access | Times Cited: 196
Treg-mediated acquired resistance to immune checkpoint inhibitors
Reem Saleh, Eyad Elkord
Cancer Letters (2019) Vol. 457, pp. 168-179
Closed Access | Times Cited: 187
Current Perspectives in Cancer Immunotherapy
Theodoulakis Christofi, Stavroula Baritaki, Luca Falzone, et al.
Cancers (2019) Vol. 11, Iss. 10, pp. 1472-1472
Open Access | Times Cited: 186
Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
Zi Mei, Junwen Huang, Bin Qiao, et al.
International Journal of Oral Science (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 186
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
Long Yuan, Jahnavi Tatineni, Kathleen M. Mahoney, et al.
Trends in Immunology (2021) Vol. 42, Iss. 3, pp. 209-227
Open Access | Times Cited: 156
Predictive biomarkers in gastric cancer
Christoph Röcken
Journal of Cancer Research and Clinical Oncology (2022) Vol. 149, Iss. 1, pp. 467-481
Open Access | Times Cited: 95
Boosting Checkpoint Immunotherapy with Biomaterials
Lujie Liu, Yuanwei Pan, Chenchen Zhao, et al.
ACS Nano (2023) Vol. 17, Iss. 4, pp. 3225-3258
Closed Access | Times Cited: 58
Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks
Lingjiao Meng, Haotian Wu, Jiaxiang Wu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 57
Novel targets for immune-checkpoint inhibition in cancer
Maxime Borgeaud, José Luís Sandoval, Michel Obéid, et al.
Cancer Treatment Reviews (2023) Vol. 120, pp. 102614-102614
Open Access | Times Cited: 53
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2718-2718
Open Access | Times Cited: 43
The B7:CD28 family and friends: Unraveling coinhibitory interactions
Kelly P. Burke, Apoorvi Chaudhri, Gordon J. Freeman, et al.
Immunity (2024) Vol. 57, Iss. 2, pp. 223-244
Open Access | Times Cited: 32
Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment
Yayuan Deng, Mengjia Shi, Yi Lin, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e37060-e37060
Open Access | Times Cited: 31
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Manshi Yang, Mengying Cui, Yang Sun, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Mechanisms of immune escape in the cancer immune cycle
Sha Tang, Qian Ning, Ling Yang, et al.
International Immunopharmacology (2020) Vol. 86, pp. 106700-106700
Closed Access | Times Cited: 128
VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity
Mohamed ElTanbouly, Walburga Croteau, Randolph J. Noelle, et al.
Seminars in Immunology (2019) Vol. 42, pp. 101308-101308
Open Access | Times Cited: 119
Combining epigenetic and immune therapy to overcome cancer resistance
Stephanie Gomez, Tomasz Tabernacki, Julie Kobyra, et al.
Seminars in Cancer Biology (2019) Vol. 65, pp. 99-113
Open Access | Times Cited: 118
Cytokines and costimulation in acute graft-versus-host disease
Geoffrey R. Hill, Motoko Koyama
Blood (2020) Vol. 136, Iss. 4, pp. 418-428
Open Access | Times Cited: 110
Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors
Aohan Hou, Kaiyu Hou, Qiubo Huang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 101
Page 1 - Next Page

Scroll to top